Endpoint analysis from EMPEROR-Preserved shows that in 5,988 adults with heart failure with LVEF over 40%, the once-daily dose of Jardiance demonstrated a 21% relative risk reduction (3.3% ...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...